Akeso's Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis

2 weeks ago 15
ARTICLE AD BOX
Read Entire Article
  1. Homepage
  2. Finance
  3. Akeso's Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis

Related

Liquidia Technologies stock surges on legal win

Liquidia Technologies stock surges on legal win

2 hours ago 1
Australians head to polls with their sights on Trump, living costs

Australians head to polls with their sights on Trump, living...

2 hours ago 1
Electronic Arts chief people officer sells shares worth $145,560

Electronic Arts chief people officer sells shares worth $145...

2 hours ago 1
RIGHT SIDEBAR TOP AD

Trending

1. james earl jones
2. baltimore weather
3. nationals vs reds
4. edwin kneedler
5. kimi antonelli
6. boxing fights tonight
7. houston weather
8. wnba schedule
9. paris fc
10. f1 tv

Popular

Paxton's challenge isn't the only one worrying Senate Republicans

Paxton's challenge isn't the only one worrying Senate Republ...

3 weeks ago 95
What we know about the New York City helicopter crash that killed 6 people

What we know about the New York City helicopter crash that k...

3 weeks ago 94
Rory McIlroy, Bryson DeChambeau surge; Justin Rose holds slim Masters lead at midway point

Rory McIlroy, Bryson DeChambeau surge; Justin Rose holds sli...

2 weeks ago 80
Biden reemerges on the attack, but doesn’t mention Trump

Biden reemerges on the attack, but doesn’t mention Trump

2 weeks ago 77
From classifying immigrants as dead to deportation: A guide to actions on Trump immigration policies

From classifying immigrants as dead to deportation: A guide ...

3 weeks ago 74
RIGHT SIDEBAR BOTTOM AD
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Powerbits - breaking news today 2025. All rights are reserved